Smallpox vaccine - Bavarian Nordic

Drug Profile

Smallpox vaccine - Bavarian Nordic

Alternative Names: IMVAMUNE; IMVAMUNE® liquid-frozen; IMVAMUNE® freeze-dried; IMVANEX; MVA-BN® Smallpox

Latest Information Update: 25 Nov 2016

Price : $50

At a glance

  • Originator Bavarian Nordic
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Smallpox

Most Recent Events

  • 23 Nov 2016 Bavarian Nordic completes enrolment in a phase III trial in Smallpox (Prevention) in South Korea
  • 20 Jul 2015 IMVAMUNE® is still in phase II trials for Smallpox (Prevention, In children, In infants) in Germany
  • 20 Jul 2015 No recent reports on development identified - Phase-II for Smallpox (Prevention) in Switzerland (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top